Cardiovascular Risk in Patients with Inflammatory Bowel Diseases-The Role of Endothelial Dysfunction

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Aug 29

PMID 39202210

Authors

Maria A Livzan

Galiya R Bikbavova

Natalya S Lisyutenko

Alisa E Romanyuk

Oxana M Drapkina

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) is associated with an increased risk of cardiovascular disease (CVD). Cardiovascular pathology in people with IBD has not been well studied to date, and a direct link between cardiovascular events and IBD has not been established. The mechanisms underlying this association include the parallel and dynamic interaction of inflammation, modulation of the composition of the gut microbiota, endothelial dysfunction, thrombogenicity, and increased endothelial and epithelial permeability. Endothelial dysfunction is a common aspect of the pathogenesis of IBD and atherosclerotic CVD and can be considered one of the most important factors leading to the development and progression of cardiovascular pathology in patients with IBD. The purpose of this literature review is to describe the mechanisms underlying the development of endothelial dysfunction and disorders of the structure and function of the gut-vascular barrier in the pathogenesis of the cardiovascular manifestation of IBD.

References

Esteve E, Castro A, Lopez-Bermejo A, Vendrell J, Ricart W, Fernandez-Real J . Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care. 2007; 30(4):939-45. DOI: 10.2337/dc06-1793. View

Turner D, Ricciuto A, Lewis A, DAmico F, Dhaliwal J, Griffiths A . STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2020; 160(5):1570-1583. DOI: 10.1053/j.gastro.2020.12.031. View

Ratajczak A, Szymczak-Tomczak A, Rychter A, Zawada A, Dobrowolska A, Krela-Kazmierczak I . Does Folic Acid Protect Patients with Inflammatory Bowel Disease from Complications?. Nutrients. 2021; 13(11). PMC: 8618862. DOI: 10.3390/nu13114036. View

Saleh T, Matta F, Yaekoub A, Danescu S, Stein P . Risk of venous thromboembolism with inflammatory bowel disease. Clin Appl Thromb Hemost. 2010; 17(3):254-8. DOI: 10.1177/1076029609360528. View

Scheiffele P, Verkade P, Fra A, Virta H, Simons K, Ikonen E . Caveolin-1 and -2 in the exocytic pathway of MDCK cells. J Cell Biol. 1998; 140(4):795-806. PMC: 2141752. DOI: 10.1083/jcb.140.4.795. View

Birchenough G, Johansson M, Gustafsson J, Bergstrom J, Hansson G . New developments in goblet cell mucus secretion and function. Mucosal Immunol. 2015; 8(4):712-9. PMC: 4631840. DOI: 10.1038/mi.2015.32. View

Gabbiadini R, Dal Buono A, Mastrorocco E, Solitano V, Repici A, Spinelli A . Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the of the issue. Front Cardiovasc Med. 2023; 10:1143293. PMC: 10227624. DOI: 10.3389/fcvm.2023.1143293. View

Razavi A, Potts K, Kelly T, Bazzano L . Sex, gut microbiome, and cardiovascular disease risk. Biol Sex Differ. 2019; 10(1):29. PMC: 6558780. DOI: 10.1186/s13293-019-0240-z. View

Nass J, Terglane J, Gerke V . Weibel Palade Bodies: Unique Secretory Organelles of Endothelial Cells that Control Blood Vessel Homeostasis. Front Cell Dev Biol. 2022; 9:813995. PMC: 8717947. DOI: 10.3389/fcell.2021.813995. View

10.

MKoma A . The Multifactorial Etiopathogeneses Interplay of Inflammatory Bowel Disease: An Overview. Gastrointest Disord (Basel). 2023; 1(1):75-105. PMC: 10416806. DOI: 10.3390/gidisord1010007. View

11.

Manninen P, Karvonen A, Huhtala H, Rasmussen M, Salo M, Mustaniemi L . Mortality in ulcerative colitis and Crohn's disease. A population-based study in Finland. J Crohns Colitis. 2012; 6(5):524-8. DOI: 10.1016/j.crohns.2011.10.009. View

12.

Medina-Leyte D, Zepeda-Garcia O, Dominguez-Perez M, Gonzalez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L . Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int J Mol Sci. 2021; 22(8). PMC: 8068178. DOI: 10.3390/ijms22083850. View

13.

Fruchart J, Nierman M, Stroes E, Kastelein J, Duriez P . New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004; 109(23 Suppl 1):III15-9. DOI: 10.1161/01.CIR.0000131513.33892.5b. View

14.

Jucan A, Gavrilescu O, Dranga M, Popa I, Mihai B, Prelipcean C . Ischemic Heart Disease in Patients with Inflammatory Bowel Disease: Risk Factors, Mechanisms and Prevention. Life (Basel). 2022; 12(8). PMC: 9331847. DOI: 10.3390/life12081113. View

15.

Dikalov S, Itani H, Richmond B, Vergeade A, Rahman S, Boutaud O . Tobacco smoking induces cardiovascular mitochondrial oxidative stress, promotes endothelial dysfunction, and enhances hypertension. Am J Physiol Heart Circ Physiol. 2019; 316(3):H639-H646. PMC: 6459311. DOI: 10.1152/ajpheart.00595.2018. View

16.

Fernandez-Hernando C, Yu J, Suarez Y, Rahner C, Davalos A, Lasuncion M . Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis. Cell Metab. 2009; 10(1):48-54. PMC: 2735117. DOI: 10.1016/j.cmet.2009.06.003. View

17.

Cross R, Wilson K . Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis. 2003; 9(3):179-89. DOI: 10.1097/00054725-200305000-00006. View

18.

Javot L, Pere P, Got I, Petitpain N, Peyrin-Biroulet L, Gillet P . Hypertrigyceridemia during infliximab therapy. Joint Bone Spine. 2013; 81(1):94-6. DOI: 10.1016/j.jbspin.2013.04.018. View

19.

Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot J, Peyrin-Biroulet L, Danese S . Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol. 2019; 4(8):643-654. DOI: 10.1016/S2468-1253(19)30173-6. View

20.

Yarur A, Deshpande A, Pechman D, Tamariz L, Abreu M, Sussman D . Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011; 106(4):741-7. DOI: 10.1038/ajg.2011.63. View